BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Mar 11, 2025 • 24min
Tour of Scotland: University of Dundee has established a world-class Centre for Protein Degradation, one of the hottest emerging modalities in biotech
Founder and Director Alessio Ciulli explains the science behind protein degradation. He then describes the facilities that have been built and the work that takes place at the centre, including founding companies like Amphista Therapeutics. Plus, his take on the field more broadly and targets that researchers are going after.
Mar 11, 2025 • 5min
Tour of Scotland: The Head of Business Development at University of Dundee's Drug Discovery Unit talks about how the university helps biopharma companies translate science into medicines
Charlotte Green describes the work that the unit does in tropical diseases, CNS, women's health, and oncology. She also highlights their pharma partnerships and licenses, and cases where independent biotech companies have spun out of the work.
Mar 11, 2025 • 10min
Tour of Scotland: Sir Michael Ferguson introduces the work in life sciences that has built up at The University of Dundee and the specialized centers that have come from it
He discusses speciality work relating to molecular cell biology / signal transduction, and translational science. Plus, the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU), the Drug Discovery Unit, the soon-to-open Innovation Hub, and more.
Mar 10, 2025 • 10min
A study published in JMIR today showed that Limbic's GenAI-powered chatbot elevated the standard of care for mental health patients in the UK’s National Health Service (NHS)
Limbic CEO Ross Harper describes how patients who interacted with Limbic Care attended 42% more therapy sessions and achieved a 25% higher recovery rate compared to standard treatment.
Mar 6, 2025 • 36min
Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated
He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus, comments on Structure Therapeutics, Corbus, Skye Bioscience, Zealand, Viking, Altimmune, Terns, and BioAge Labs.
Feb 28, 2025 • 12min
On Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy science
Matthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the improvements in vector delivery capabilities, and improving the yield and lowering the cost of future treatments, that is possible with the latest generation of gene therapy.
Feb 26, 2025 • 7min
Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL
CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program targeting BRD9, and how the company thinks about partnerships going forward.
Feb 26, 2025 • 7min
Cambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer them
Co-Founder and CEO Sam Windsor describes the rationale for using AI to focus more on tox, not efficacy, and gives and example of a drug the company has already in-licensed from a pharma company. Plus, what today's raise will enable the company to do.
Feb 26, 2025 • 15min
With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline
CEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese partner, an IL18, ZIP12, and more.
Feb 24, 2025 • 23min
From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers
He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.
